论文部分内容阅读
将收治入院的2型糖尿病肾病患者共40例,分为两组,治疗组(诺和龙20例),对照组(诺和锐30 20例),疗程3个月,评价及比较两组血糖控制情况,并记录服药期间的副作用。结果治疗3个月时,两组FBG、2h PBG、及HbAlc水平均有明显下降,(P<0.05)。与对照组相比,治疗组低血糖发生率明显低。结论诺和龙与诺和锐30治疗2型糖尿病肾病患者时都能取得良好效果,诺和龙低血糖现象发生较少,相对较安全。
A total of 40 patients with type 2 diabetic nephropathy admitted to hospital were divided into two groups: treatment group (Novo-Long 20 cases) and control group (Novo-Rui 30 20 cases) for 3 months. The levels of blood glucose Control the situation and record side effects during the medication. Results Three months after treatment, FBG, 2h PBG and HbAlc levels in both groups decreased significantly (P <0.05). Compared with the control group, the incidence of hypoglycemia in the treatment group was significantly lower. Conclusion Novo-Long and Novo-Rui-30 treatment of patients with type 2 diabetic nephropathy can achieve good results, Novo Nordisk low incidence of hypoglycemia, relatively safe.